To investigate if ibrutinib and nutlin-3 were able to target microenvironment-protected leukemia cells, primary B-CLL cells co-cultured with stroma or stimulated with CpG-ODN and CD40L were treated with the two drugs used alone or in pharmacological combination. The gene discussed is CD40LG; the disease is B-cell chronic lymphocytic leukemia.